Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data I read the ...
Impact of KRAS mutation status on outcomes in peritoneal metastatic mucinous adenocarcinoma of the colon and appendix following CRS-HIPEC: A retrospective analysis. The addition of monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results